Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

414

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped due to futility as per protocol

Conditions

Infectious Pneumonia
Severe COVID-19

Interventions

DRUG: Reparixin
OTHER: Placebo

Sponsor

Dompé Farmaceutici S.p.A